Compare Novo Nordisk A/S (NVO) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SPDR Kensho Final Frontiers ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while SPDR Kensho Final Frontiers ETF trades at $103.49 (market cap $170.14M). The key difference: Novo Nordisk A/S is far larger — about 971.6× SPDR Kensho Final Frontiers ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while SPDR Kensho Final Frontiers ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and SPDR Kensho Final Frontiers ETF for 9 Days on average.
| NVO | ROKT | |
|---|---|---|
Market Cap | $165.31B | $170.14M |
Volume | 11,432,838 | 12,298 |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $136.68 |
52-Week Low | $35.29 | $72.93 |
Typical Hold Time | 116 Days | 9 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
